title: Does synchronous endometrioid endometrial cancer have any prognostic effect on Stage I endometrioid ovarian cancer?
abstract: OBJECTIVE
  To determine the effect of synchronous endometrial endometrioid cancer (SEEC) on the prognosis of patients with Stage 1 endometrioid ovarian cancer (EOC).
  
  
  METHODS
  Clinicopathological data of cases with Stage 1 EOC from January 2000 to November 2013 were retrieved from the computerized database of Etlik Zubeyde Hanim Women's Health and Research Hospital. Of the 31 patients included in the study, 15 patients had primary synchronous endometrial and ovarian cancer (SEOC) (Group 1) and 16 patients had EOC alone (Group 2).
  
  
  RESULTS
  Ovarian cancer substage and grade were compared between the two groups, and no significant differences were found. Most of the patients with SEEC had Grade 1 tumours (n=13, 86.7%). In Group 1, nine (60.0%) patients had endometrial tumours with superficial myometrial invasion, and six (40.0%) patients had deep myometrial invasion. Median follow-up was 94 months. Ten-year disease-free survival rates were 92.9% for Group 1 and 84.6% for Group 2 (p=0.565).
  
  
  CONCLUSIONS
  Patients with Stage 1 EOC have excellent long-term survival. The presence of SEEC does not influence the prognosis of patients with Stage 1 EOC, even in the presence of deep myometrial invasion.
authors.affiliation: Erzincan University Faculty of Medicine, Division of Gynaecologic Oncology, Erzincan, Turkey. Electronic address: mali_narin@yahoo.com.
authors.forename: M A
authors.initials: MA
authors.lastname: Narin
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: A
authors.initials: A
authors.lastname: Karalok
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: D
authors.initials: D
authors.lastname: Basaran
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: I
authors.initials: I
authors.lastname: Ureyen
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: O
authors.initials: O
authors.lastname: Turkmen
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: T
authors.initials: T
authors.lastname: Turan
authors.affiliation: Etlik Zubeyde Hanim Women's Health Teaching and Research Hospital, Gynecologic Oncology Department, Etlik, Keçiören, Ankara, Turkey.
authors.forename: G
authors.initials: G
authors.lastname: Tulunay
mesh_terms: D000328:Adult; D018269:Carcinoma, Endometrioid / Q000473:pathology*; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000473:pathology*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009215:Myometrium / Q000473:pathology; D009361:Neoplasm Invasiveness; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000473:pathology*; D010051:Ovarian Neoplasms / Q000473:pathology*; D011379:Prognosis
keywords: Endometrial cancer; Ovarian cancer; Survival; Synchronous cancers